Irwin Naturals Announces California Settlement of Investigation into Mislabeling and False Advertising

Below is a press release issued by Irwin Naturals about its settlement of an investigation into its mislabeling and falsely advertising some of its products under California Law: Irwin Naturals, one of the nation’s leading suppliers of natural dietary and herbal supplements, announces that it has reached a settlement with a California task force that [...]

FDA Commissioner Attempts to Curb Regulated Drug Use in Nutritional Supplements

With an ongoing rise in nutritional supplements containing chemicals regulated as drugs, the Commissioner of the Food and Drug Administration recently sent a letter to all manufacturers of dietary supplements reminding them of their concern of this matter and their plans to reduce the problem. The purpose of the letter is stated as to “address [...]

What marketing draws the ire of the FDA?

Marketers of nutritional supplements often complain that they do not know what the FDA wants. Even after the agency sends a warning letter about misleading claims and advertising, its staff does not explain what would fall within the rules. That’s the reality; the FDA will tell you what’s wrong, not what’s right. Through warning letters, [...]

No more kicking around the vitamin hustlers

David Frum could have lowered his rhetorical blood pressure in his CNN.com guest commentary on the evils of dietary supplement marketing by reading the FTC regulations that go into effect on Tuesday. His column then would have begun: The party is over Dec. 1.

Google: A line for drug warnings

Two days of hearings before the FDA about search-based advertising for drugs produced one possible solution: fixed warnings for products. Google has proposed that its AdWords could include a hyperlinked line that warns consumers about the potential dangers of a drug.

Supplement advertising could hinge on FDA hearings

On Nov. 12, drugmakers and search-engine advertising agencies participated in about 30 presentations before the FDA. The hearing room was so crowded that most people seeking an audience seat were turned away. What did the company executives say?